These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 32812835)

  • 41. Comparison of biological activity among nonfucosylated therapeutic IgG1 antibodies with three different N-linked Fc oligosaccharides: the high-mannose, hybrid, and complex types.
    Kanda Y; Yamada T; Mori K; Okazaki A; Inoue M; Kitajima-Miyama K; Kuni-Kamochi R; Nakano R; Yano K; Kakita S; Shitara K; Satoh M
    Glycobiology; 2007 Jan; 17(1):104-18. PubMed ID: 17012310
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Highly sensitive HPLC analysis and biophysical characterization of N-glycans of IgG-Fc domain in comparison between CHO and 293 cells using FcγRIIIa ligand.
    Kosuge H; Nagatoishi S; Kiyoshi M; Ishii-Watabe A; Tanaka T; Terao Y; Oe S; Ide T; Tsumoto K
    Biotechnol Prog; 2020 Nov; 36(6):e3016. PubMed ID: 32390308
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Characterization of IgG1 Fc Deamidation at Asparagine 325 and Its Impact on Antibody-dependent Cell-mediated Cytotoxicity and FcγRIIIa Binding.
    Lu X; Machiesky LA; De Mel N; Du Q; Xu W; Washabaugh M; Jiang XR; Wang J
    Sci Rep; 2020 Jan; 10(1):383. PubMed ID: 31941950
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Afucosylated antibodies increase activation of FcγRIIIa-dependent signaling components to intensify processes promoting ADCC.
    Liu SD; Chalouni C; Young JC; Junttila TT; Sliwkowski MX; Lowe JB
    Cancer Immunol Res; 2015 Feb; 3(2):173-83. PubMed ID: 25387893
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Section 1C: Assessment of the functional activity and IgG Fc receptor utilisation of 64 IgG Rh monoclonal antibodies. Coordinator's report.
    Kumpel BM; Beliard R; Brossard Y; Edelman L; de Haas M; Jackson DJ; Kooyman P; Ligthart PC; Monchâtre E; Overbeeke MA; Puillandre P; de Romeuf C; Wilkes AM
    Transfus Clin Biol; 2002 Jan; 9(1):45-53. PubMed ID: 11889899
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Crystal structure of a novel asymmetrically engineered Fc variant with improved affinity for FcγRs.
    Mimoto F; Kadono S; Katada H; Igawa T; Kamikawa T; Hattori K
    Mol Immunol; 2014 Mar; 58(1):132-8. PubMed ID: 24334029
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Impacts of fast production of afucosylated antibodies and Fc mutants in ExpiCHO-S™ for enhancing FcγRIIIa binding and NK cell activation.
    Zhong X; Schenk J; Sakorafas P; Chamberland J; Tam A; Thomas LM; Yan G; D' Antona AM; Lin L; Nocula-Lugowska M; Zhang Y; Sousa E; Cohen J; Gu L; Abel M; Donahue J; Lim S; Meade C; Zhou J; Riegel L; Birch A; Fennell BJ; Franklin E; Gomes JM; Tzvetkova B; Scarcelli JJ
    J Biotechnol; 2022 Dec; 360():79-91. PubMed ID: 36341973
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Knobs-into-holes antibody production in mammalian cell lines reveals that asymmetric afucosylation is sufficient for full antibody-dependent cellular cytotoxicity.
    Shatz W; Chung S; Li B; Marshall B; Tejada M; Phung W; Sandoval W; Kelley RF; Scheer JM
    MAbs; 2013; 5(6):872-81. PubMed ID: 23995614
    [TBL] [Abstract][Full Text] [Related]  

  • 49. In vitro glycoengineering of IgG1 and its effect on Fc receptor binding and ADCC activity.
    Thomann M; Schlothauer T; Dashivets T; Malik S; Avenal C; Bulau P; Rüger P; Reusch D
    PLoS One; 2015; 10(8):e0134949. PubMed ID: 26266936
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Control of therapeutic IgG antibodies galactosylation during cultivation process and its impact on IgG1/FcγR interaction and ADCC activity.
    Simonov V; Ivanov S; Smolov M; Abbasova S; Piskunov A; Poteryaev D
    Biologicals; 2019 Mar; 58():16-21. PubMed ID: 30655169
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Expression of GnTIII in a recombinant anti-CD20 CHO production cell line: Expression of antibodies with altered glycoforms leads to an increase in ADCC through higher affinity for FC gamma RIII.
    Davies J; Jiang L; Pan LZ; LaBarre MJ; Anderson D; Reff M
    Biotechnol Bioeng; 2001 Aug; 74(4):288-94. PubMed ID: 11410853
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Role of Fc Core Fucosylation in the Effector Function of IgG1 Antibodies.
    Golay J; Andrea AE; Cattaneo I
    Front Immunol; 2022; 13():929895. PubMed ID: 35844552
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Modulating IgG effector function by Fc glycan engineering.
    Li T; DiLillo DJ; Bournazos S; Giddens JP; Ravetch JV; Wang LX
    Proc Natl Acad Sci U S A; 2017 Mar; 114(13):3485-3490. PubMed ID: 28289219
    [TBL] [Abstract][Full Text] [Related]  

  • 54. An Fc engineering approach that modulates antibody-dependent cytokine release without altering cell-killing functions.
    Kinder M; Greenplate AR; Strohl WR; Jordan RE; Brezski RJ
    MAbs; 2015; 7(3):494-504. PubMed ID: 25933349
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Characterization of FcγRIIIA effector cells used in in vitro ADCC bioassay: Comparison of primary NK cells with engineered NK-92 and Jurkat T cells.
    Hsieh YT; Aggarwal P; Cirelli D; Gu L; Surowy T; Mozier NM
    J Immunol Methods; 2017 Feb; 441():56-66. PubMed ID: 27939300
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Inhibiting N-glycan processing increases the antibody binding affinity and effector function of human natural killer cells.
    Rodriguez Benavente MC; Hughes HB; Kremer PG; Subedi GP; Barb AW
    Immunology; 2023 Oct; 170(2):202-213. PubMed ID: 37218360
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Nonfucosylated therapeutic IgG1 antibody can evade the inhibitory effect of serum immunoglobulin G on antibody-dependent cellular cytotoxicity through its high binding to FcgammaRIIIa.
    Iida S; Misaka H; Inoue M; Shibata M; Nakano R; Yamane-Ohnuki N; Wakitani M; Yano K; Shitara K; Satoh M
    Clin Cancer Res; 2006 May; 12(9):2879-87. PubMed ID: 16675584
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Preparation and biological activities of anti-HER2 monoclonal antibodies with fully core-fucosylated homogeneous bi-antennary complex-type glycans.
    Tsukimura W; Kurogochi M; Mori M; Osumi K; Matsuda A; Takegawa K; Furukawa K; Shirai T
    Biosci Biotechnol Biochem; 2017 Dec; 81(12):2353-2359. PubMed ID: 29090617
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Structural and functional characterization of MBS301, an afucosylated bispecific anti-HER2 antibody.
    Huang S; Li F; Liu H; Ye P; Fan X; Yuan X; Wu Z; Chen J; Jin C; Shen B; Feng J; Zhang B
    MAbs; 2018; 10(6):864-875. PubMed ID: 30081724
    [TBL] [Abstract][Full Text] [Related]  

  • 60. GA201 (RG7160): a novel, humanized, glycoengineered anti-EGFR antibody with enhanced ADCC and superior in vivo efficacy compared with cetuximab.
    Gerdes CA; Nicolini VG; Herter S; van Puijenbroek E; Lang S; Roemmele M; Moessner E; Freytag O; Friess T; Ries CH; Bossenmaier B; Mueller HJ; Umaña P
    Clin Cancer Res; 2013 Mar; 19(5):1126-38. PubMed ID: 23209031
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.